1-(苯磺酰基)-1H-吲哚-2-羧酸 | 40899-93-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-(苯磺酰基)-1H-吲哚-2-羧酸
• 英文名称: 1-(phenylsulfonyl)-1H-indole-2-carboxylic acid
• 英文别名: 1-phenylsulfonyl-1H-indole-2-carboxylic acid；1-phenylsulfonyl-1H-2-indolecarboxylic acid；1-(phenylsulfonyl)indole-2-carboxylic acid；N-benzenesulfonylindole-2-carboxylic acid；1-benzenesulfonyl-indole-2-carboxylic acid；1-(phenylsulphonyl)indole-2-carboxylic acid；1-(benzenesulfonyl)indole-2-carboxylic acid
• CAS: 40899-93-2
• 化学式: C₁₅H₁₁NO₄S
• 分子量: 301.323
• InChiKey: QIWDUGKJAHJRAE-UHFFFAOYSA-N

物化性质

• 熔点：
  170 °C
• 沸点：
  570.7±42.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090

SDS

Name:	1-(Phenylsulfonyl)-1h-indole-2-carboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	40899-93-2

Section 1 - Chemical Product MSDS Name:1-(Phenylsulfonyl)-1h-indole-2-carboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
40899-93-2	1-(Phenylsulfonyl)-1H-indole-2-carboxy	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 40899-93-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 180 - 182 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H11NO4S
Molecular Weight: 301.32

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 40899-93-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(Phenylsulfonyl)-1H-indole-2-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 40899-93-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 40899-93-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 40899-93-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(苯磺酰基)-1H-吲哚-2-羧酸 在 氯化亚砜 作用下， 反应 3.0h， 生成 1-苯基磺酰-1H-吲哚-2-羰酰氯
  参考文献：
  名称：

  Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors

  摘要：

  该发明涉及公式（I）的化合物：其中R1代表吡唑基或吲唑基，R2和R3特别代表H、卤素、羟基、硝基、氰基、R4、—OR4、—COR4、—OC(═O)R4、—C(═O)OR4、—C(═O)OH、—N(R5)C(═O)R4、—N(R5)C(═O)OR4、—S(O)nR4、—S(O)nOR4、—N(R5)SO2R4、—NY1Y2、—C(═O)NY1Y2、—N(R5)C(═O)NY1Y2、—S(O)nNY1Y2和—OC(═O)NY1Y2，其中R4特别代表烷基、烯基、环烷基、芳基、杂芳基和杂环烷基，R5特别代表H、烷基、烯基、环烷基、杂环烷基、芳基和杂芳基，Y1和Y2特别代表H、烷基、烯基、环烷基、杂环烷基、芳基、芳基羧基、杂芳基和杂芳基羧基，可以选择地被取代，或者Y1和Y2与N形成氨基环，n代表0至2，所有这些基团都可以选择地被取代，这些产品以所有异构体形式和盐的形式作为药物产品，特别作为KDR抑制剂。

  公开号：

  US20040242559A1
• 作为产物：
  描述：

  吲哚-2-羧酸甲酯 在 lithium hydroxide monohydrate 、 水 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 1-(苯磺酰基)-1H-吲哚-2-羧酸
  参考文献：
  名称：

  [EN] INHIBITORS OF HEPATITIS B VIRUS COVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE
  [FR] INHIBITEURS D'UNE FORMATION D'ADN CIRCULAIRE FERMÉE DE FAÇON COVALENTE DU VIRUS DE L'HÉPATITE B ET LEUR PROCÉDÉ D'UTILISATION

  摘要：

  公开号：

  WO2013130703A3

文献信息

• Fragment-Based Design, Synthesis, and Biological Evaluation of 1-Substituted-indole-2-carboxylic Acids as Selective Mcl-1 Inhibitors
  作者：Ziqian Wang、Wenjie Xu、Ting Song、Zongwei Guo、Lu Liu、Yudan Fan、Anhui Wang、Zhichao Zhang

  DOI：10.1002/ardp.201600251

  日期：2017.1

  Based on a known selective Mcl‐1 inhibitor, 6‐chloro‐3‐(3‐(4‐chloro‐3,5‐dimethylphenoxy)propyl)‐1H‐indole‐2‐carboxylic acid, we applied a fragment‐based approach to obtain new molecules that extended into the p1 pocket of the BH3 groove and then exhibited binding selectivity for the Mcl‐1 over the Bcl‐2 protein. After we deconstructed the 1H‐indole‐2‐carboxylic acid from the parental molecule, a benzenesulfonyl

  基于已知的选择性 Mcl-1 抑制剂 6-氯-3-(3-(4-氯-3,5-二甲基苯氧基)丙基)-1H-吲哚-2-羧酸，我们采用基于片段的方法获得延伸到 BH3 凹槽 p1 口袋的新分子，然后表现出对 Mcl-1 的结合选择性，而不是 Bcl-2 蛋白。在我们从母体分子中解构出 1H-吲哚-2-羧酸后，根据 X 射线鉴定的母体分子的结合模式，在 1 位取代了苯磺酰基以采用优选的几何形状来访问 p1 口袋晶体学。在分子生长以占据 p1 口袋的过程中，配体结合的自由能 (ΔG) 与非氢重原子数 (HAC) 之间保持线性关系。最后，我们不仅得到了化合物 12 的 7。对 Mcl-1 的选择性比 Bcl-2（Ki = 3.6 µM）高 5 倍（荧光偏振的 Ki = 0.48 µM），但也提供了证据表明 p1 口袋的额外占用对 Mcl-1 比对 Bcl-更有利2 结合，对 Mcl-1 抑制的贡献大于对
• N-(피페리딘-4-일)-1H-인돌-2-카복스아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-Ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY 한국화학연구원(319980077651)

  公开号：KR101725451B1

  公开（公告）日：2017-04-13

  본 발명은 N-(피페리딘-4-일)-1H-인돌-2-카복스아마이드 유도체, 이의 제조방법, 및 이를 유효성분으로 포함하는 유로텐신-Ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 N-(피페리딘-4-일)-1H-인돌-2-카복스아마이드 유도체는 유로텐신-Ⅱ 수용체에 대한 길항제로 작용함으로써 울혈성 심부전, 심장 허혈, 심근경색, 심장 비대증, 심장 섬유증, 관상동맥 질환, 동맥경화증, 고혈압, 천식, 신부전, 당뇨병, 혈관염증, 신경퇴행성 질환, 뇌졸중, 통증, 정신병, 암 등과 같은 유로텐신-Ⅱ 수용체 활성 관련 질환을 예방 또는 치료하는데 유용하게 사용할 수 있다.

  本发明涉及N-(吡啶-4-基)-1H-吲哚-2-羧酰胺衍生物，其制备方法，以及包含其作为有效成分的用于预防或治疗与欧洲肽-II受体活性相关的疾病的药学组合物。根据本发明，N-(吡啶-4-基)-1H-吲哚-2-羧酰胺衍生物通过作为欧洲肽-II受体的拮抗剂而可用于预防或治疗与欧洲肽-II受体活性相关的疾病，如充血性心力衰竭、心脏缺血、心肌梗死、心脏肥大、心脏纤维化、冠状动脉疾病、动脉硬化、高血压、哮喘、肾功能不全、糖尿病、血管炎、神经退行性疾病、脑卒中、疼痛、精神疾病、癌症等。
• Hypervalent Iodine(III) Mediated Decarboxylative Halogenation of Indolecarboxylic Acids for the Synthesis of Haloindole Derivatives
  作者：Yasuyoshi Miki、Hiromi Hamamoto、Hideaki Umemoto、Misako Umemoto、Chiaki Ohta、Masashi Dohshita

  DOI：10.1055/s-0030-1258585

  日期：2010.10

  The treatment of 1-methylindole-2,3-dicarboxylic acid with hypervalent iodine(III) reagent, phenyliodine diacetate (PI-DA), in the presence of lithium bromide gave 1-methyl-3,3-dibromooxindole. However, the reaction of 1-(phenylsulfonyl)indole-2,3-dicarboxylic acid with PIDA in the presence of lithium bromide afforded 2,3-dibromo-1-(phenylsulfonyl)indole. In a similar manner, the 2,3-dichloro- and

  在溴化锂存在下，用高价碘 (III) 试剂、二乙酸苯碘 (PI-DA) 处理 1-甲基吲哚-2,3-二羧酸得到 1-甲基-3,3-二溴吲哚。然而，在溴化锂存在下，1-(苯基磺酰基)吲哚-2,3-二羧酸与PIDA反应得到2,3-二溴-1-(苯基磺酰基)吲哚。以类似的方式，2,3-二氯-和2,3-二碘-吲哚衍生物是通过吲哚-2,3-二羧酸与PIDA在氯化锂和碘化锂存在下的反应获得的。
• Magnesiation of indoles with magnesium amide bases
  作者：Yoshinori Kondo、Akihiro Yoshida、Takao Sakamoto

  DOI：10.1039/p19960002331

  日期：——

  1-Substituted indole derivatives are deprotonated with Hauser bases (R2NMgBr) or magnesium diamide [(R2N)2Mg] to give magnesioindoles which are then reacted with electrophiles.

  用Hauser碱（R 2 NMgBr）或二酰胺镁[（R 2 N）2 Mg]对1-取代的吲哚衍生物进行质子化处理，得到镁吲哚，然后使其与亲电试剂反应。
• [EN] SUBSTITUTED INDOLES WITH SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] INDOLES SUBSTITUES DOTES D'UNE AFFINITE POUR LE RECEPTEUR DE LA SEROTONINE, LEUR PROCEDE DE FABRICATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SUVEN LIFE SCIENCES LTD

  公开号：WO2004108671A1

  公开（公告）日：2004-12-16

  The present invention relates to the compounds represented by general formula (I) as shown below.

  本发明涉及如下所示的一般式(I)所代表的化合物。